Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 7/20 | 0.61 |
| ▸ | AURKA | O14965 | 7/20 | 0.57 |
| ▸ | INSR | P06213 | 3/20 | 0.55 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.55 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4842982 | 0.76 | AURKA (0.68) | TBK1AURKAIKBKEPRMT5 | |
| SCHEMBL4843679 | 0.76 | TBK1 (0.78) | TBK1INSRALKIKBKE | |
| SCHEMBL4844250 | 0.74 | TBK1 (0.58) | TBK1AURKAIKBKE | |
| SCHEMBL4843136 | 0.74 | TBK1 (0.74) | TBK1AURKAIKBKEKCNH2 | |
| SCHEMBL17290061 | 0.72 | PARP1 (0.46) | TBK1AURKAINSRALKCNR2 | |
| SCHEMBL4186428 | 0.71 | AURKA (0.52) | TBK1AURKAINSRALKKCNH2 | |
| SCHEMBL17306376 | 0.71 | PARP1 (0.45) | TBK1INSRALKCNR2 | |
| SCHEMBL4834884 | 0.70 | TBK1 (0.75) | TBK1IKBKE | |
| SCHEMBL17289610 | 0.69 | PARP1 (0.51) | TBK1INSRALKPRMT5CNR2 | |
| SCHEMBL4834315 | 0.69 | TBK1 (0.73) | TBK1IKBKE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539759-B1 | NOVEL IMIDAZOPYRIDINES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | claimed |
| US-7410966-B2 | Use of and some novel imidazopyridines | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | disclosed |
| EP-1539759-B1 | NOVEL IMIDAZOPYRIDINES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | disclosed |
| US-20050261333-A1 | Use of and some novel imidazopyridines | ASTRAZENECA A B (SE) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261333-A1 | Use of and some novel imidazopyridines | ITK, CSNK1A1, RPS6KA1 | TBK1 1029/4885AURKA 512/4885INSR 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.